Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Eric Schmidt FCA
CANT
Eric Schmidt FCA
Cantor Fitzgerald
Wall Street Analyst
★★★☆☆
#1395
on 13Foresight · ranked by our own returns
56%
Success Rate
+31.3%
Average Return
10 of 18 calls profitable · +15.1% vs benchmark
📈 Across the calls we could measure, roughly 56% of Eric Schmidt FCA's ratings turned a profit when each position was held for 1 year — averaging +31.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

21 Buy 5 Hold 0 Sell
Eric's Stock Coverage 21 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
PRIM
Primoris Services
 Jun 17, 2026 HOLD Strong Buy
+26.1% avg upside
19 analysts
$124.00
22.49% Upside
 +0.0%
ODTX
Odyssey Therapeutics, Inc.
 Jun 02, 2026 BUY Strong Buy
+67.8% avg upside
5 analysts
 — ·
LONA
LeonaBio
 Apr 07, 2026 BUY Buy
+13.9% avg upside
9 analysts
 — -3.6%
GENB
Generate Biomedicines, Inc.
 Mar 24, 2026 BUY Strong Buy
+76.8% avg upside
6 analysts
 — ·
SRRK
Scholar Rock Holding
 Mar 19, 2026 BUY Strong Buy
+20.2% avg upside
23 analysts
 — +3.2%
LEGN
Legend Biotech
 Dec 17, 2025 BUY Strong Buy
+134.2% avg upside
27 analysts
$74.00
164.99% Upside
 +67.5%
VSTM
Verastem
 Oct 16, 2025 BUY Strong Buy
+259.4% avg upside
23 analysts
 — -57.9%
ALMS
Alumis Inc.
 Aug 14, 2025 BUY Strong Buy
+63.6% avg upside
11 analysts
 — +444.0%
BBOT
BridgeBio Oncology Therapeutics
 Aug 13, 2025 BUY Strong Buy
+231.7% avg upside
10 analysts
 — -21.6%
BBIO
BridgeBio Pharma
 Aug 13, 2025 BUY Strong Buy
+38.3% avg upside
34 analysts
 — +33.8%
SMMT
Summit Therapeutics
 Jul 28, 2025 BUY Strong Buy
+112.6% avg upside
27 analysts
 — -49.5%
IMVT
Immunovant
 Jul 25, 2025 BUY Strong Buy
+9.0% avg upside
24 analysts
 — +104.8%
PRTA
Prothena
 Jun 20, 2025 HOLD Buy
+160.9% avg upside
14 analysts
 — +48.4%
IMTX
Immatics
 Jun 02, 2025 BUY Strong Buy
+87.3% avg upside
15 analysts
 — +80.9%
AGIO
Agios Pharma
 May 13, 2025 BUY Strong Buy
+73.8% avg upside
29 analysts
 — +0.1%
CBIO
Crescent Biopharma
 Mar 21, 2025 BUY Strong Buy
+26.4% avg upside
17 analysts
 — ·
BIIB
Biogen
 Feb 05, 2025 BUY Strong Buy
+25.1% avg upside
51 analysts
$206.00
4.76% Upside
 +27.4%
ADCT
ADC Therapeutics
 May 30, 2024 BUY Buy
+450.4% avg upside
12 analysts
 — -10.2%
INCY
Incyte
 Apr 23, 2024 HOLD Buy
+1.0% avg upside
47 analysts
 — +12.3%
TNGX
Tango Therapeutics
 Apr 04, 2024 BUY Strong Buy
+24.2% avg upside
14 analysts
 — -83.4%
IMCR
Immunocore Holdings
 Nov 02, 2023 BUY Strong Buy
+124.5% avg upside
22 analysts
 — -31.9%
🔒 16 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Eric Schmidt FCA — Frequently Asked Questions
How accurate are Eric Schmidt FCA's stock ratings?
Based on the calls 13Foresight could measure, about 56% of Eric's ratings were profitable over a one-year hold, with an average return of +31.3% per rating, or +15.1% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Eric ranked on 13Foresight?
Eric Schmidt FCA is currently ranked #1395 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Eric cover?
Eric most recently has ratings on PRIM, ODTX, LONA, GENB, SRRK, LEGN, VSTM, ALMS, BBOT, BBIO, SMMT, IMVT and 9 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.